Russell Investments Group Ltd. Acquires 8,309 Shares of Eli Lilly and Company (NYSE:LLY)

Russell Investments Group Ltd. raised its holdings in Eli Lilly and Company (NYSE:LLY) by 1.6% in the fourth quarter, HoldingsChannel.com reports. The firm owned 516,804 shares of the company’s stock after purchasing an additional 8,309 shares during the quarter. Eli Lilly and Company comprises approximately 0.5% of Russell Investments Group Ltd.’s holdings, making the stock its 19th biggest holding. Russell Investments Group Ltd.’s holdings in Eli Lilly and Company were worth $301,107,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. Lipe & Dalton acquired a new position in shares of Eli Lilly and Company in the 4th quarter valued at approximately $26,000. Thompson Investment Management Inc. acquired a new position in shares of Eli Lilly and Company in the 3rd quarter valued at approximately $27,000. Legacy Financial Group LLC acquired a new position in shares of Eli Lilly and Company in the 3rd quarter valued at approximately $35,000. Optiver Holding B.V. acquired a new position in shares of Eli Lilly and Company in the 3rd quarter valued at approximately $36,000. Finally, Family CFO Inc acquired a new position in shares of Eli Lilly and Company in the 3rd quarter valued at approximately $40,000. Institutional investors own 82.53% of the company’s stock.

Insider Buying and Selling

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 54,032 shares of the firm’s stock in a transaction on Monday, January 29th. The shares were sold at an average price of $645.07, for a total value of $34,854,422.24. Following the transaction, the insider now directly owns 99,488,598 shares of the company’s stock, valued at $64,177,109,911.86. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.13% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

LLY has been the subject of several analyst reports. Cantor Fitzgerald restated an “overweight” rating and issued a $815.00 target price on shares of Eli Lilly and Company in a research report on Monday, April 15th. Wells Fargo & Company upped their price objective on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. DZ Bank cut shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price objective for the company. in a research report on Wednesday, February 21st. The Goldman Sachs Group upped their price objective on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research report on Thursday, April 11th. Finally, Citigroup upped their price objective on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research report on Tuesday, April 2nd. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $728.05.

Eli Lilly and Company Stock Up 1.2 %

NYSE LLY traded up $8.64 on Friday, hitting $733.51. 2,009,249 shares of the company were exchanged, compared to its average volume of 2,265,427. The company has a market cap of $696.95 billion, a PE ratio of 126.47, a PEG ratio of 1.58 and a beta of 0.34. Eli Lilly and Company has a 12 month low of $380.77 and a 12 month high of $800.78. The stock has a fifty day moving average of $761.79 and a 200-day moving average of $666.06. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.19. The business had revenue of $9.35 billion for the quarter, compared to analyst estimates of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. Eli Lilly and Company’s revenue was up 28.1% on a year-over-year basis. During the same period in the prior year, the firm earned $2.09 earnings per share. As a group, analysts forecast that Eli Lilly and Company will post 12.51 earnings per share for the current year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.